Abstract: A method is described. The method includes receiving system level power information. The method includes causing a power supply unit's voltage conversion switching frequency to change based on the system level power information. The power supply unit supplies power to a system that includes at least a processor and memory. The system level power information describes power consumed by at least the processor and memory.

Abstract: A device may obtain customer data, associated with a customer identifier, that includes an indication of a recency of a past purchase, a frequency of past purchases, and/or a monetary value associated with past purchases by a customer associated with the customer identifier. The device may determine, based on comparing the customer data and aggregate customer data, a first score that predicts a current measure of loyalty associated with the customer, and may predict, based on the first score, a predicted frequency of future purchases by the customer and a predicted monetary value associated with the future purchases, to determine a second score that predicts a future measure of loyalty associated with the customer. The device may compare the first score and the second score to determine a risk level associated with the customer, and may cause an action to be performed based on determining the risk level.

Abstract: Present invention relates to a formulation from natural product. The formulation is LDV liposomal formulation of Photo System-I (PSI) which causes apoptotic death of cancer cells through ROS generation and a simple way for targeted delivery of the said formulation specifically to melanoma cancer cell. LDV liposomal formulation of PSI was prepared for targeted delivery to melanoma cancer cell. Through this targeted delivery inventors have shown that LDV liposomal formulation of PSI specifically kills melanoma cancer cells leaving normal cells unaffected. The present invention elucidates that LDV liposomal formulation of PSI is more potent anti-cancer agent than doxorubicin for melanoma.

Abstract: A device may obtain customer data, associated with a customer identifier, that includes an indication of a recency of a past purchase, a frequency of past purchases, and/or a monetary value associated with past purchases by a customer associated with the customer identifier. The device may determine, based on comparing the customer data and aggregate customer data, a first score that predicts a current measure of loyalty associated with the customer, and may predict, based on the first score, a predicted frequency of future purchases by the customer and a predicted monetary value associated with the future purchases, to determine a second score that predicts a future measure of loyalty associated with the customer. The device may compare the first score and the second score to determine a risk level associated with the customer, and may cause an action to be performed based on determining the risk level.

Abstract: The present investigation involves designing of a novel hexapeptide, which spontaneously self-assembles to form nanovesicles in physiological conditions. This peptide not only strongly binds with ?-tubulin near taxol binding site, but also binds with microtubule lattice in-vitro, as well as intracellular microtubule networks. Interestingly, it inhibits amyloid fibril formation upon co-incubation with A? peptide in-vitro and shows excellent neuroprotection against A? infected neuronal cell (PC12). Present invention provides a novel approach to produce a peptide-based therapeutics for neurodegenerative disease.

Abstract: The present investigation involves designing of a novel hexapeptide, which spontaneously self-assembles to form nanovesicles in physiological conditions. This peptide not only strongly binds with ?-tubulin near taxol binding site, but also binds with microtubule lattice in-vitro, as well as intracellular microtubule networks. Interestingly, it inhibits amyloid fibril formation upon co-incubation with A? peptide in-vitro and shows excellent neuroprotection against A? infected neuronal cell (PC12). Present invention provides a novel approach to produce a peptide-based therapeutics for neurodegenerative disease.